15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English News: Gilead tops table for antivirals
查看: 820|回复: 1
go

News: Gilead tops table for antivirals [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2012-1-27 10:07 |只看该作者 |倒序浏览 |打印
        Gilead tops table for antivirals        World News | January 26, 2012
        [url=http://www.pharmatimes.com/Article/12-01-26/href=%22http://www.addthis.com/bookmark.php?v=250&username=sarahbullard%22][/url]

       


        

        
Kevin Grogan     

   
            
With combined sales from the top HIV treatment on the market, Atripla, and several other drugs, Gilead Sciences leads the antiviral market, closely followed by Bristol-Myers Squibb, Roche and Merck & Co.
That is the key point in a report from Kalorama Information, the healthcare market research firm, which notes that the market for all anti-infectives reached $53 billion in 2011. It points out that Atripla (efavirenz/tenofovir/emtricitabine) is expected to bring in $3.2 billion in sales in 2011 and the HIV drugs Truvada (emtricitabine/tenofovir) and Viread (tenofovir), plus the hepatitis B drug Hepsera (adefovir) are performing well.
However, in a highly competitive market, other companies are gaining, the analysis notes. B-MS is second, driven by its nucleoside analogue Baraclude (entecavir) for hepatitis B; its sales have grown from $257 million in 2007 to $1.1 billion now. As for the firm's HIV drugs, the Sustiva (efavirenz) franchise and Reyataz (atazanavir) are growing steadily.
Roche holds the third market position overall, helped by Pegasys (peginterferon alfa-2a), for hepatitis B and C, the transplantation product Valcyte (valganciclovir) and the influenza jab Tamiflu (oseltamivir). At the end of last year, the Swiss major announced plans to acquire the USA's Anadys Pharmaceuticals, a hepatitis C specialist, for around $230 million.
Kalorama notes that GlaxoSmithKline alone accounted for 25% of the antiviral market in 2009, but has since declined due to patent expirations.  on key products. However its HIV joint venture with Pfizer, ViiV Healthcare, accounted for one-tenth of the antiviral drug market in 2011.

        
    Links            www.kaloramainformation.com

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2012-1-27 10:53 |只看该作者
从结合市场上顶端的艾滋病毒治疗,Atripla,和其他一些药物的销售,Gilead Sciences公司领导的抗病毒药物市场,紧接着由施贵宝,罗氏公司和默克制药公司
从卡洛拉马信息的报告,医疗保健市场研究公司,该公司指出,所有抗感染药市场在2011年达到530亿美元,这是关键点。它点出,Atripla(依非韦伦/替诺福韦/恩曲他滨)是预计到在32亿美元的销售额带来2011和的艾滋病毒药物Truvada(恩曲他滨/替诺福韦)和Viread(替诺福韦),加的肝炎乙药物Hepsera(阿德福韦酯)是执行以及。
然而,在激烈的市场竞争,其他公司获得,分析说明。 B - MS是第二,乙型肝炎的核苷类似物博路定(恩替卡韦)的带动下,其销售额2007年的257万美元增长到1.1亿美元。至于该公司的抗艾滋病毒药物,Sustiva(efavirenz的)的专营权和Reyataz(阿扎那韦)也在稳步增长。
罗氏公司拥有三分之一的市场地位,总体而言,派罗欣(聚乙二醇干扰素α-2a),乙型肝炎和丙型肝炎,移植产品Valcyte(缬更昔洛韦)和流感JAB达菲(奥司他韦)的帮助。在去年年底,瑞士主要宣布计划收购美国Anadys制药,丙型肝炎专科,为230亿美元左右。
卡洛拉马指出,葛兰素史克公司就占了在2009年的抗病毒药物市场的25%,但此后下降由于专利到期。重点产品。但其艾滋病毒与辉瑞公司,欢跃医疗,合资企业占抗病毒药物市场在2011年的十分之一。
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-1 07:51 , Processed in 0.013164 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.